Department of Health
and Human Services (HHS)
and Human Services (HHS)
July 21, 2020
RFA-CA-20-033 - SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)
National Cancer Institute (NCI)
The purpose of this Notice is to revise the “Key Dates” of RFA-CA-20-033, and revise the guidance provided in Section IV.7 for “Post Submission Materials”.
1. Part 1 Key Dates in RFA-CA-20-033 Currently Reads:
Open Date (Earliest Submission Date)
July 3, 2020
Letter of Intent Due Date(s)
July 3, 2020
Application Due Date(s)
August 3, 2020. All applications are due by 5:00 PM local time of applicant organization.
Scientific Merit Review
October/November 2020
Earliest Start Date
April 1, 2021
Expiration Date
August 04, 2020
2. Part 1 Key Dates in RFA-CA-20-033 Modified (by this Notice) to Read (in italics):
Open Date (Earliest Submission Date)
July 31, 2020
Letter of Intent Due Date(s)
July 31, 2020
Application Due Date(s)
August 31, 2020. All applications are due by 5:00 PM local time of applicant organization.
Scientific Merit Review
November 2020
Earliest Start Date
May 1, 2021
Expiration Date
September 01, 2020
3. Section IV.7 Post Submission Materials Currently reads:
Applicants are required to follow the instructions for post-submission materials, as described in the policy. Any instructions provided here are in addition to the instructions in the policy.
4. Section IV.7 Post Submission Materials Modified (by this Notice) to Read (in italics):
Applicants are required to follow the instructions for post-submission materials, as described in the policy to be read with the following changes due to the ongoing COVID-19 situation.
Letters of Support:
Letters of Support may be submitted up to 30-days prior to the review
Additional preliminary data:
Applicants should refer to NOT-OD-20-123 for “Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic”
Update to fundraising plan:
Applicants may provide a one-page update to the fundraising plan section of their “Commercialization Plan”, this may be submitted up to 30-days prior to the review.
Documentation of support from third-party investors:
Documentation of support from third-party investors may be submitted up to 30-days prior to the review.
Note: All other aspects of RFA-CA-20-033 remain unchanged.
Jonathan Franca-Koh, Ph.D., M.B.A.
National Cancer Institute (NCI)
Telephone: 240-618-0984
Email: jonathan.franca-koh@nih.gov